Drugs / INV-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06938204 | Apr → Aug 2024 | — | Innovo Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04531150 | Sep 2020 → Jan 2021 | — | Inversago Pharma Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05844592 Comparator | Apr → Jul 2022 | ulcerative colitis | Innovo Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INV-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04531150 ↗ |
| Route | Oral | “Single Ascending Oral Doses of INV-101” NCT04531150 ↗ |